The study hypothesis is that BCG na茂ve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with鈥�
- Investigator
- Padraic O'Malley
- Ages
- 18 Years - N/A
- Sexes
- All